Tenofovir alafenamide(TAF) — Competitive Intelligence Brief

Tenofovir alafenamide(TAF) (Tenofovir alafenamide(TAF)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor (NtRTI). Area: Infectious Disease / Virology.

marketed Nucleotide reverse transcriptase inhibitor (NtRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Tenofovir alafenamide(TAF) (Tenofovir alafenamide(TAF)) — Humanity and Health Research Centre. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tenofovir alafenamide(TAF) TARGET	Tenofovir alafenamide(TAF)	Humanity and Health Research Centre	marketed	Nucleotide reverse transcriptase inhibitor (NtRTI)	HIV reverse transcriptase
Emtricitabine/tenofovir or abacavir/lamivudine	Emtricitabine/tenofovir or abacavir/lamivudine	Fundacion SEIMC-GESIDA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Lamivudine/Zidovudine	Lamivudine/Zidovudine	Bristol-Myers Squibb	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil	elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil	Fundacion Clinic per a la Recerca Biomédica	marketed	Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, CYP3A4, HIV reverse transcriptase
All licensed antiretroviral medications	All licensed antiretroviral medications	University of Minnesota	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)
emtricitabine [FTC]/tenofovir [TDF]	emtricitabine [FTC]/tenofovir [TDF]	Tibotec, Inc	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
nucleoside reverse transcriptase inhibitors	nucleoside reverse transcriptase inhibitors	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor (NtRTI) class)

1. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
2. Humanity and Health Research Centre · 1 drug in this class
3. New Discovery LLC · 1 drug in this class
4. ViiV Healthcare · 1 drug in this class